37.16
price up icon0.69%   0.255
after-market 시간 외 거래: 37.17 0.005 +0.01%
loading
전일 마감가:
$36.91
열려 있는:
$37.2
하루 거래량:
930.19K
Relative Volume:
1.01
시가총액:
$3.22B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-5.7442
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
+9.21%
1개월 성능:
+6.00%
6개월 성능:
-24.74%
1년 성능:
-11.02%
1일 변동 폭
Value
$36.50
$37.48
1주일 범위
Value
$34.10
$37.48
52주 변동 폭
Value
$29.59
$60.37

울트라제닉스 파마슈티컬 Stock (RARE) Company Profile

Name
명칭
Ultragenyx Pharmaceutical Inc
Name
전화
415-483-8800
Name
주소
60 LEVERONI COURT, NOVATO, CA
Name
직원
1,294
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
RARE's Discussions on Twitter

RARE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
37.16 3.22B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-28 개시 William Blair Outperform
2024-06-06 업그레이드 Goldman Neutral → Buy
2024-04-22 개시 RBC Capital Mkts Outperform
2023-12-08 개시 Wells Fargo Overweight
2023-06-14 재개 Credit Suisse Outperform
2023-06-06 업그레이드 Evercore ISI In-line → Outperform
2023-04-26 개시 Cantor Fitzgerald Overweight
2023-01-18 재개 Canaccord Genuity Buy
2022-12-30 재개 H.C. Wainwright Buy
2022-11-03 업그레이드 Robert W. Baird Neutral → Outperform
2022-10-13 업그레이드 Guggenheim Neutral → Buy
2022-08-01 다운그레이드 Evercore ISI Outperform → In-line
2022-03-16 업그레이드 Credit Suisse Neutral → Outperform
2022-02-11 업그레이드 JP Morgan Neutral → Overweight
2021-09-30 개시 H.C. Wainwright Buy
2021-08-19 개시 UBS Sell
2021-07-15 개시 Guggenheim Neutral
2021-06-29 업그레이드 BofA Securities Neutral → Buy
2021-06-04 재개 Robert W. Baird Neutral
2021-05-06 업그레이드 Citigroup Neutral → Buy
2021-05-06 업그레이드 Evercore ISI In-line → Outperform
2021-04-26 재개 Credit Suisse Neutral
2021-03-02 재개 Stifel Buy
2021-02-12 다운그레이드 JP Morgan Overweight → Neutral
2020-12-07 다운그레이드 Wedbush Outperform → Neutral
2020-11-24 재개 Evercore ISI In-line
2020-11-12 다운그레이드 BofA Securities Buy → Neutral
2019-08-02 재개 Wedbush Outperform
2019-03-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-02-22 재개 Raymond James Outperform
2019-01-02 다운그레이드 Raymond James Outperform → Mkt Perform
2018-11-08 업그레이드 Citigroup Sell → Neutral
2018-09-10 개시 Morgan Stanley Equal-Weight
2018-06-21 다운그레이드 Credit Suisse Outperform → Neutral
2018-05-11 업그레이드 Barclays Equal Weight → Overweight
2018-05-10 개시 Goldman Neutral
2018-04-18 업그레이드 SunTrust Hold → Buy
2018-03-22 재개 Piper Jaffray Overweight
2018-02-21 재확인 Stifel Buy
2018-01-22 업그레이드 Evercore ISI In-line → Outperform
2018-01-18 개시 Credit Suisse Outperform
2017-12-05 재확인 Barclays Equal Weight
2017-12-04 업그레이드 Jefferies Hold → Buy
2017-09-14 업그레이드 Wedbush Neutral → Outperform
모두보기

울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스

pulisher
Jun 05, 2025

Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat

Jun 05, 2025
pulisher
Jun 05, 2025

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan

Jun 03, 2025
pulisher
May 29, 2025

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com

May 29, 2025
pulisher
May 29, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World

May 29, 2025
pulisher
May 28, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq

May 28, 2025
pulisher
May 28, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN

May 28, 2025
pulisher
May 28, 2025

William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga

May 28, 2025
pulisher
May 28, 2025

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga

May 28, 2025
pulisher
May 28, 2025

Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com

May 28, 2025
pulisher
May 28, 2025

Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus

May 28, 2025
pulisher
May 26, 2025

Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com

May 26, 2025
pulisher
May 25, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria

May 25, 2025
pulisher
May 25, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com

May 25, 2025
pulisher
May 21, 2025

CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com

May 21, 2025
pulisher
May 21, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 21, 2025
pulisher
May 20, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN

May 20, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com

May 14, 2025
pulisher
May 13, 2025

Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com

May 12, 2025
pulisher
May 09, 2025

RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmace - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com

May 09, 2025
pulisher
May 09, 2025

RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmaceutical | RARE Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st

May 09, 2025
pulisher
May 09, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y - MSN

May 09, 2025
pulisher
May 09, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Ultragenyx to Participate at Bank of America's 2025 Healthcare C - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Ultragenyx price target lowered to $100 from $140 at Truist - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being - simplywall.st

May 08, 2025
pulisher
May 08, 2025

Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE) - The Globe and Mail

May 08, 2025
pulisher
May 08, 2025

Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Decoding Ultragenyx Pharmaceutical Inc (RARE): A Strategic SWOT Insight - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Ultragenyx Reports Strong Growth Amid Challenges - TipRanks

May 07, 2025

울트라제닉스 파마슈티컬 (RARE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

울트라제닉스 파마슈티컬 주식 (RARE) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Crombez Eric
EVP and Chief Medical Officer
Apr 21 '25
Sale
35.11
242
8,497
71,680
Horn Howard
Chief Financial Officer
Mar 06 '25
Sale
40.40
1,785
72,114
106,169
Kassberg Thomas Richard
CBO & EVP
Mar 03 '25
Sale
42.10
6,028
253,779
265,238
Parschauer Karah Herdman
EVP and Chief Legal Officer
Mar 03 '25
Sale
42.10
12,846
540,817
75,287
Crombez Eric
EVP and Chief Medical Officer
Mar 03 '25
Sale
42.10
8,945
376,584
71,922
Pinion John Richard
See Remarks
Mar 03 '25
Sale
42.10
14,439
607,882
107,766
KAKKIS EMIL D
President & CEO
Mar 03 '25
Sale
42.10
73,434
3,091,571
641,731
KAKKIS EMIL D
President & CEO
Feb 28 '25
Sale
42.48
25,000
1,062,000
2,158,985
Harris Erik
EVP & Chief Commercial Officer
Mar 03 '25
Sale
42.10
15,103
635,836
87,855
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Mar 03 '25
Sale
42.10
967
40,711
50,265
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
자본화:     |  볼륨(24시간):